Women's Health Issues
Volume 17, Issue 6 , Pages 338-341 , November 2007

Changes in Postmenopausal Hormone Therapy Use Since 1988

  • Jung Ki Kim, PhD

      Affiliations

    • Andrus Gerontology Center, University of Southern California, Los Angeles, California
    • Jung Ki Kim is a Research Assistant Professor at Andrus Gerontology Center, University of Southern California. She received her PhD in Gerontology from the University of Southern California, and her current research is on biological risks and population health.
    • Corresponding Author InformationCorrespondence to: Jung Ki Kim, PhD, Andrus Gerontology Center, University of Southern California, Los Angeles, CA 90089-0191; phone: 213-740-0794; fax: 213-740-0787.
    • ,
  • Dawn Alley, PhD

      Affiliations

    • Robert Wood Johnson Health and Society Scholars Program, University of Pennsylvania, Philadelphia, Pennsylvania
    • Dawn Alley is a Robert Wood Johnson Health and Society Scholar at University of Pennsylvania. She received her PhD in Gerontology from the University of Southern California, and her current research is on biomarkers and health trajectories among older people.
    • ,
  • Peifeng Hu, MD, PhD

      Affiliations

    • Division of Geriatrics, UCLA School of Medicine, Los Angeles, California
    • Peifeng Hu is an Assistant Professor in the Division of Geriatrics at the David Geffen School of Medicine at the University of California, Los Angeles. He received his MD from the Shanghai Medical University, and his current research is on inflammation markers, antioxidants and aging.
    • ,
  • Arun Karlamangla, MD, PhD

      Affiliations

    • Division of Geriatrics, UCLA School of Medicine, Los Angeles, California
    • Arun Karlamangla is an Assistant Professor in the Division of Geriatrics at the David Geffen School of Medicine at the University of California, Los Angeles. He received his MD from the University of Michigan School of Medicine, and his current research is in the epidemiology of age-related diseases and functional decline.
    • ,
  • Teresa Seeman, PhD

      Affiliations

    • Division of Geriatrics, UCLA School of Medicine, Los Angeles, California
    • Teresa Seeman is a Professor in the Division of Geriatrics at the David Geffen School of Medicine at the University of California, Los Angeles. She received her PhD in Epidemiology from the University of California Berkeley, and her current research is on the biological mechanisms for social and psychological effects on health risks.
    • ,
  • Eileen M. Crimmins, PhD

      Affiliations

    • Andrus Gerontology Center, University of Southern California, Los Angeles, California
    • Eileen M. Crimmins is the Edna M. Jones Professor of Gerontology at the Andrus Gerontology Center, University of Southern California. She received her PhD in Demography from the University of Pennsylvania, and her current research is on biological risks, healthy life expectancy, and population health.

Received 10 April 2007 ,Accepted 2 May 2007.

References 

  1. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Annals of Internal Medicine. 1992;117:1039–1041
  2. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. American Journal of Epidemiology. 1997;145:536–545
  3. Bruist DS, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, et al. Hormone therapy prescribing patterns in the United States. Obstetrics and Gynecology. 2004;104:1042–1050
  4. Cushman M, Legault C, Barrett-Connor E, Stefanick M, Kessler C, Judd H, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999;100:717–722
  5. Ettinger B, Grady D, Tosteson A, Pressman A, Macer J. Effect of the Women’s Health Initiative on women’s decisions to discontinue postmenopausal hormone therapy. Obstetrics and Gynecology. 2003;102:1225–1232
  6. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clinical Chemistry. 2004;50:574–581
  7. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Annals of Internal Medicine. 2004;140:184–188
  8. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger W, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. American Journal of Medicine. 1999;106:506–512
  9. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy (Annual trends and response to recent evidence). Journal of the American Medical Association. 2004;291:47–53
  10. Hing E, Brett KM. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003. Obstetrics and Gynecology. 2006;108:4–5
  11. Kelly JP, Kaufman DW, Rosenberg L, Kelley K, Cooper SG, Mitchell AA. Use of postmenopausal hormone therapy since the Women’s Health Initiative findings. Pharmacoepidemiology and Drug Safety. 2005;14:837–842
  12. Kim JK, Alley D, Seeman T, Karlamangla A, Crimmins E. Recent changes in cardiovascular risk factors among women and men. Journal of Women’s Health. 2006;15:734–746
  13. Koenig W, Sund M, Frohlich M, Fischer H, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA Augsburg Cohort Study, 1984–1992. Circulation. 1999;99:237–242
  14. North American Menopause Society. Amended report from the NAMS advisory panel on postmenopausal hormone therapy. Menopause. 2003;10:6–12
  15. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of The North American Menopause Society. Menopause. 2003;10:497–506
  16. North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause. 2004;11:589–600
  17. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association. 2001;286:327–334
  18. Pradhan A, Manson J, Rossouw J, Siscovick D, Mouton C, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease prospective analysis from the Women’s Health Initiative Observational Study. Journal of the American Medical Association. 2002;288:980–987
  19. Ravdin PM, Cronin KA, Howlander N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast-cancer incidence in 2003 in the United States. New England Journal of Medicine. 2007;356:1670–1674
  20. Reuben DB, Cheh AI, Harris TB, Ferrucci L, Rowe JW, Tracy RP, et al. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. Journal of the American Geriatrics Society. 2002;50:638–644
  21. Ridker PM, Glynn RJ, Hennekens CH. CRP adds to the predictive value of total and HDL cholesterol in determining risk of first MI. Circulation. 1998;97:2007–2011
  22. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713–716
  23. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. Journal of the American Medical Association. 2002;288:321–333
  24. Schonberg MA, Davis RB, Wee CC. After the Women’s Health Initiative: Decision making and trust of women taking hormone therapy. Women’s Health Issues. 2005;15:187–195
  25. Smith SC, Anderson JL, Cannon RO, Fadl Y, Koenig W, Libby P, et al. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice report from the Clinical Practice Discussion Group. Circulation. 2004;110:e550–e553

 Supported by grants R01 AG023347, T32 AG00037, K12AG01004 and P30 AG17265 from the National Institute on Aging (NIA).

PII: S1049-3867(07)00062-X

doi: 10.1016/j.whi.2007.05.001

Women's Health Issues
Volume 17, Issue 6 , Pages 338-341 , November 2007

Article Tools

* Image Usage & Resolution